Back to Journals » OncoTargets and Therapy » Volume 9

miR-125b inhibited epithelialal–mesenchymal transition of triple-negative breast cancer by targeting MAP2K7

Authors Hong L, Pan F, Jiang H, Zhang L, Liu Y, Cai C, Hua C, Luo X, Sun J, Chen Z

Received 17 December 2015

Accepted for publication 14 March 2016

Published 4 May 2016 Volume 2016:9 Pages 2639—2648

DOI https://doi.org/10.2147/OTT.S102713

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati


Liquan Hong,1 Feng Pan,1 Huifen Jiang,2 Lahong Zhang,1 Yuhua Liu,1 Chengsong Cai,1 Chunzhen Hua,3 Xian Luo,1 Jinhua Sun,4 Zhaojun Chen1

1Department of Clinical Laboratory, Affiliated Hospital of Hangzhou Normal University, 2Zhejiang Provincial Tumor Hospital, 3Zhejiang Provincial Children’s Hospital, 4Technology Department, Hangzhou Joingenome Diagnostics, Hangzhou, Zhejiang Province, People’s Republic of China

Abstract: MicroRNAs (miRNAs) play important roles in diverse biological processes and are emerging as key regulators of tumorigenesis and tumor progression. Among the differentially expressed miRNAs in breast cancer, miR-125b was revealed to be deregulated and associated with poor prognosis and chemoresistance in triple-negative breast cancer (TNBC), but the mechanism is still unknown. In our study, we showed downregulated expression of miR-125b in TNBC tissues and decreased migration and invasion in miR-125b-expressing Hs578T cells. MAP2K7 was then detected to be a novel target of miR-125b, and downregulation of MAP2K7 by miR-125b was similar to transient knockdown of MAP2K7 which hindered epithelial–­mesenchymal transition (EMT) of Hs578T cells. Upregulation of MAP2K7 in miR-125b-overexpressing Hs578T cells partly rescued the migration and invasion suppression of miR-125b. Furthermore, MAP2K7 was overexpressed in TNBC samples compared with normal tissues and negatively correlated with miR-125b expression. In light of these findings, miR-125b emerged as a tumor suppressor in TNBC by targeting MAP2K7 to inhibit EMT.

Keywords: miR-125b, MAP2K7, TNBC, Hs578T, EMT

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]